Illumina (ILMN) Q2 2026 Earnings Call Transcript
Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY2026 revenue, ROW organic growth, and non-GAAP EPS guidance, alongside NovaSeq X transition progress and clinical consumables growth. Offsetting factors include research and applied consumables decline and margin headwinds from freight and memory costs.
Market read
Raised guidance and strong NovaSeq X and clinical consumables momentum are likely to drive near-term re-rating, while research-market funding caution and cost pressures are the main swing factors.
What to watch
Gross margin was pressured by higher freight and memory costs; traders may need to watch whether inventory de-risking and cost absorption are temporary or structural into 2026.
Background
This is a transcript-style summary of Illumina’s Q2 2026 earnings call, including financial results, guidance updates, and product and platform transition commentary.
Ticker impact
Illumina raised FY2026 revenue guidance to $4.60B-$4.64B and FY non-GAAP EPS to $5.30-$5.40 after Q2 results and NovaSeq X momentum.
Bias toward upside revisions and multiple support, with volatility tied to whether research and applied consumables stabilize and freight/memory costs normalize.
The article provides multiple concrete, decision-relevant datapoints: Q2 revenue/EPS beats, raised full-year guidance ranges, NovaSeq X transition metrics (83% of volumes, 59% of revenue), and explicit margin drivers (freight and memory costs).
Market effects
Supports the sequencing-instruments and clinical consumables demand narrative, but highlights margin sensitivity to freight and memory costs.
U.S.-Canada clinical growth is flagged as the primary driver, implying regional demand strength may matter for near-term read-throughs.
Rest-of-world organic growth guidance was increased, suggesting broader ex-China demand resilience despite research-market funding caution.
Counterpoint
The guidance raise may be offset by continued weakness in research and applied consumables (7% decline) and ongoing customer funding uncertainty, limiting upside follow-through.
Key entities
- companyIllumina
Sequencing and multiomics platform provider reporting Q2 2026 results and raising full-year guidance.
- executiveJacob Thaysen
CEO cited cautious customer spending in research markets and discussed NovaSeq X momentum.
- executiveAnkur Dhingra
CFO discussed margin impacts from freight and memory costs and inventory actions to manage memory price risk.
- programBillion Cell Atlas
Biopharma partnership program generating data revenue; reached 300 million cells delivered and added three partners in the quarter.
